Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/184262
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Rio Fernández, Antonio del | - |
dc.contributor.author | Garcia de la Mària, Cristina | - |
dc.contributor.author | Entenza, José Manuel | - |
dc.contributor.author | Gasch, Oriol | - |
dc.contributor.author | Armero, Yolanda | - |
dc.contributor.author | Soy Muner, Dolors | - |
dc.contributor.author | Mestres Lucio, Carlos-Alberto | - |
dc.contributor.author | Pericàs, Juan M. | - |
dc.contributor.author | Falces Salvador, Carles | - |
dc.contributor.author | Ninot, Salvador | - |
dc.contributor.author | Almela, M. (Manel) | - |
dc.contributor.author | Cervera, Carlos | - |
dc.contributor.author | Gatell, José M. | - |
dc.contributor.author | Moreno Camacho, Ma. Asunción | - |
dc.contributor.author | Moreillon, Philippe | - |
dc.contributor.author | Marco Reverté, Francesc | - |
dc.contributor.author | Miró Meda, José M. | - |
dc.contributor.author | Hospital Clínic Experimental Endocarditis Study Group | - |
dc.date.accessioned | 2022-03-21T12:30:04Z | - |
dc.date.available | 2022-03-21T12:30:04Z | - |
dc.date.issued | 2016-01-01 | - |
dc.identifier.issn | 1098-6596 | - |
dc.identifier.uri | http://hdl.handle.net/2445/184262 | - |
dc.description.abstract | The urgent need of effective therapies for methicillin-resistant Staphylococcus aureus (MRSA) infective endocarditis (IE) is a cause of concern. We aimed to ascertain the in vitro and in vivo activity of the older antibiotic fosfomycin combined with different beta-lactams against MRSA and glycopeptide-intermediate-resistant S. aureus (GISA) strains. Time-kill tests with 10 isolates showed that fosfomycin plus imipenem (FOF+IPM) was the most active evaluated combination. In an aortic valve IE model with two strains (MRSA-277H and GISA-ATCC 700788), the following intravenous regimens were compared: fosfomycin (2 g every 8 h [q8h]) plus imipenem (1 g q6h) or ceftriaxone (2 g q12h) (FOF+CRO) and vancomycin at a standard dose (VAN-SD) (1 g q12h) and a high dose (VAN-HD) (1 g q6h). Whereas a significant reduction of MRSA-227H load in the vegetations (veg) was observed with FOF+IPM compared with VAN-SD (0 [interquartile range [IQR], 0 to 1] versus 2 [IQR, 0 to 5.1] log CFU/g veg; P = 0.01), no statistical differences were found with VAN-HD. In addition, FOF+IPM sterilized more vegetations than VAN-SD (11/15 [73%] versus 5/16 [31%]; P = 0.02). The GISA-ATCC 700788 load in the vegetations was significantly lower after FOF+IPM or FOF+CRO treatment than with VAN-SD (2 [IQR, 0 to 2] and 0 [IQR, 0 to 2] versus 6.5 [IQR, 2 to 6.9] log CFU/g veg; P < 0.01). The number of sterilized vegetations after treatment with FOF+CRO was higher than after treatment with VAN-SD or VAN-HD (8/15 [53%] versus 4/20 [20%] or 4/20 [20%]; P = 0.03). To assess the effect of FOF+IPM on penicillin binding protein (PBP) synthesis, molecular studies were performed, with results showing that FOF+IPM treatment significantly decreased PBP1, PBP2 (but not PBP2a), and PBP3 synthesis. These results allow clinicians to consider the use of FOF+IPM or FOF+CRO to treat MRSA or GISA IE.Copyright © 2015, American Society for Microbiology. All Rights Reserved. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | American Society for Microbiology | - |
dc.relation.isformatof | Reproducció del postprint publicat a: https://doi.org/10.1128/AAC.02139-15 | - |
dc.relation.ispartof | Antimicrobial Agents And Chemotherapy, 2015, vol 60, num 1, p. 478-486 | - |
dc.relation.uri | https://doi.org/10.1128/AAC.02139-15 | - |
dc.rights | (c) American Society for Microbiology, 2015 | - |
dc.source | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) | - |
dc.subject.classification | Endocarditis | - |
dc.subject.classification | Antibiòtics | - |
dc.subject.other | Endocarditis | - |
dc.subject.other | Antibiotics | - |
dc.title | Fosfomycin plus Beta-lactams: Synergistic Bactericidal Combinations in Methicillin-resistant (MRSA) and Glycopeptide-Intermediate Resistant (GISA) Staphylococcus aureus Experimental Endocarditis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.date.updated | 2022-03-21T10:36:35Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 2030417 | - |
dc.identifier.pmid | 26525803 | - |
dc.identifier.pmid | 26525803 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
12474_2030417_aac02139-15_clean_revised__manuscript.pdf | 387.02 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.